CG Results Healthcare has advised Noramco on the divestment of its API site in Rhode Island, USA, to Pharmaron
- Service: Divestments
- Sector: Healthcare
- Sub Sector: CROs & CMOs
- Engagement Type: Sell Side
CG Results Healthcare is pleased to announce that it has advised Noramco, a leading speciality API developer and manufacturer, on the divestment of its API manufacturing site in Coventry, Rhode Island, to Pharmaron.
The Coventry site has an established history of cGMP small molecule API manufacturing from pilot kilogram to commercial metric ton scales and its state-of-the-art manufacturing facilities have been inspected and approved by the FDA, EMA and other regulatory authorities.
Pharmaron acquired the facility to expand its chemistry and manufacturing services into the USA, an important step in establishing its global platform. Existing capabilities at Coventry add to Pharmaron’s array of services, strengthening its ability to offer partners customised chemistry and manufacturing solutions around the world.
This cross-border transaction is CG Results Healthcare’s fourth successful manufacturing asset divestment this year, underlining our industry leadership in this space and ability to complete transactions globally.